

Investor Relations | Hologic

FDA Grants PMA Approval for Hologic's Aptima® Hepatitis C Quant Dx Assay

HCV viral load test now available alongside HIV-1 assay and women's health menu on the fully automated Panther system

MARLBOROUGH, Mass., Feb. 15, 2017 /[PRNewswire](#)/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the United States Food and Drug Administration (FDA) has granted PMA approval for the Company's hepatitis C virus (HCV) assay for quantitation of HCV viral load and confirming active HCV infection on the fully automated Panther® system.

"HCV therapeutic options continue to evolve rapidly with highly effective antiviral medications that are transforming treatment of the disease, with cure rates above 90%," said Tom West, president, Diagnostic Solutions Division at Hologic. "The expanded use of the Aptima HCV Quant Dx assay to confirm active HCV infection in addition to viral load quantitation will help physicians more quickly determine the best treatment options and help improve patient care."

The Aptima HCV Quant Dx assay uses real-time transcription-mediated amplification (TMA), which provides highly sensitive and specific performance for diagnostic use, as well as reliable quantitation for determination of sustained antiviral response across all major genotypes and a wide linear range. The assay runs on the Panther system, which provides full sample to answer automation and substantially reduces hands-on time with random and continuous access.

The Aptima HCV Quant Dx assay joins a growing list of tests available on the Panther system in the U.S. market. In addition to an HIV-1 (human immunodeficiency virus) viral load assay, the Panther menu includes tests for sexually transmitted infections – chlamydia, gonorrhea, trichomonas and human papillomavirus (HPV).

"Menu consolidation is increasingly important to clinical laboratories in their efforts to increase efficiency of operations," said West. "Expanding the range of assays that can be run on the Panther system with offerings in virology, in addition to women's health, will help our customers reach their goals."

Hologic has a long-term legacy in the virology space, beginning two decades ago and spanning development of nucleic acid tests to screen the blood supply for HIV, HCV and HBV, an expertise that was applied to the development of the viral load portfolio on the Panther system.

In Europe, the Aptima HCV Quant Dx assay is CE-IVD marked for diagnostic and viral load monitoring, as is the Aptima HIV-1 Quant Dx assay. The Aptima HBV (hepatitis B) Quant assay is CE-IVD marked for viral load monitoring but is not currently approved for sale in the United States. To learn more about the Aptima Quant assays available in the United States, please visit <http://usaptimavirology.com>.

About Hologic

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products. The company's core business units focus on diagnostics, breast health, GYN surgical, and skeletal health. With a unified suite of technologies and a robust research and development program, Hologic is dedicated to The Science of Sure. For more information on Hologic, visit www.hologic.com.

Hologic Forward-Looking Statements

This press release may contain forward-looking information that involves risks and uncertainties,

including statements about the use of Hologic's diagnostic products. There can be no assurance these products will achieve the benefits described herein or that such benefits will be replicated in any particular manner with respect to an individual patient. The actual effect of the use of the products can only be determined on a case-by-case basis depending on the particular circumstances and patient in question. In addition, there can be no assurance that these products will be commercially successful or achieve any expected level of sales. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based.

Hologic, The Science of Sure, Aptima and Panther are registered trademarks of Hologic, Inc. in the United States and/or other countries.

Hologic Investor Contact

Michael Watts

Vice President, Investor Relations and Corporate Communications

+1 (858) 410-8588

michael.watts@hologic.com

Hologic Media Contact

Jane Mazur

Senior Director, Divisional Communications

+1 (585) 355-5978

jane.mazur@hologic.com

SOURCE Hologic, Inc.

<http://investors.hologic.com/2017-02-15-FDA-Grants-PMA-Approval-for-Hologics-Aptima-R-Hepatitis-C-Quant-Dx-Assay>